{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:16:04Z","timestamp":1793103364003,"version":"4.5.0"},"reference-count":37,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: This systematic review evaluated the impact of nusinersen therapy on respiratory health and function in individuals with spinal muscular atrophy (SMA) and determined whether nusinersen improves pulmonary function, focusing on differences based on patient age and the timing of treatment initiation. Methods: A systematic search of PubMed, Ovid Medline, ScienceDirect, and Web of Science databases was conducted up to January 2024 in accordance with the PRISMA guidelines. Thirteen studies were included, comprising clinical trials, observational studies, and case series that focused on respiratory outcomes in SMA patients treated with nusinersen. The data on study design, participant characteristics, nusinersen intervention, respiratory outcomes, and adverse events were extracted. The Joanna Briggs Institute Critical Appraisal Tool was used to assess study quality. A narrative synthesis was conducted to address the heterogeneity of the studies. Results: This review found a general trend of improvement in pulmonary function, specifically in forced vital capacity (FVC), although the extent and duration of improvement varied across the studies. Peak cough flow (PCF) and peak expiratory flow (PEF) showed positive trends in some studies, although the results were not consistently significant. Respiratory function improvements were frequently observed, particularly in younger patients and those treated earlier. Conclusions: Nusinersen appears to enhance respiratory function and improve motor outcomes in SMA patients, especially with early treatment. However, further research is needed to fully understand its mechanisms and long-term effects on respiratory health in SMA.<\/jats:p>","DOI":"10.3390\/jcm13216306","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:53:43Z","timestamp":1729583623000},"page":"6306","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Impact of Nusinersen Treatment on Respiratory Function in Patients with Spinal Muscular Atrophy: A Systematic Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Mona","family":"Aldukain","sequence":"first","affiliation":[{"name":"Faculty of Medicine, King Khaled University, Abha 62521, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aldukain","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, King Khaled University, Abha 62521, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assal","family":"Hobani","sequence":"additional","affiliation":[{"name":"College of Medicine, Ibn Sina National College, Jeddah 22421, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmalik","family":"Barakat","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujain","family":"Alsayyed","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, King Khaled University, Abha 62521, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Alomar","sequence":"additional","affiliation":[{"name":"College of Medicine, Sulaiman Al Rajhi University, Al-Bukairiyah 52726, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5634-8432","authenticated-orcid":false,"given":"Maha Saad","family":"Zain Al-Abeden","sequence":"additional","affiliation":[{"name":"College of Medicine, Sulaiman Al Rajhi University, Al-Bukairiyah 52726, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Alzoum","sequence":"additional","affiliation":[{"name":"College of Medicine, Princess Nourah bint Abdulrahaman University, Riyadh 11671, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-9789","authenticated-orcid":false,"given":"Ali Alsuheel","family":"Asseri","sequence":"additional","affiliation":[{"name":"Department of Child Health, College of Medicine, King Khalid University, Abha 62529, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014A literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative Analyses of SMN1 and SMN2 Based on Real-Time LightCycler PCR: Fast and Highly Reliable Carrier Testing and Prediction of Severity of Spinal Muscular Atrophy","volume":"70","author":"Schwarzer","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s41983-022-00572-9","article-title":"Psychological burden in spinal muscular atrophy patients and their families: A systematic review","volume":"58","author":"Sari","year":"2022","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-022-02227-7","article-title":"Natural history of respiratory muscle strength in spinal muscular atrophy: A prospective national cohort study","volume":"17","author":"Veldhoen","year":"2022","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","author":"Farrar","year":"2013","journal-title":"J. Pediatr."},{"key":"ref_8","first-page":"18","article-title":"The role of sleep diagnostics and non-invasive ventilation in children with spinal muscular atrophy","volume":"28","author":"Grychtol","year":"2018","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: First Global Approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40261-017-0557-5","article-title":"Nusinersen: The First Option Beyond Supportive Care for Spinal Muscular Atrophy","volume":"37","author":"Maharshi","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: Current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Elsheikh, B., Severyn, S., Zhao, S., Kline, D., Linsenmayer, M., Kelly, K., Tellez, M., Bartlett, A., Heintzman, S., and Reynolds, J. (2021). Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.650532"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., and Brennan, S.E. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. The BMJ, 372.","DOI":"10.1136\/bmj.n71"},{"key":"ref_14","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2024). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Updated August 2024), Cochrane. Available online: www.training.cochrane.org\/handbook."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews: Methodological development, conduct and reporting of an Umbrella review approach","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int. J. Evid. Based Healthc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1007\/s00415-023-11711-4","article-title":"An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy","volume":"270","author":"Bjelica","year":"2023","journal-title":"J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejpn.2021.02.007","article-title":"Nusinersen does not improve lung function in a cohort of children with spinal muscular atrophy\u2014A single-center retrospective study","volume":"31","author":"Heitschmidt","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen","volume":"219","author":"Sansone","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014A prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E317","DOI":"10.1212\/CPJ.0000000000001033","article-title":"Nusinersen Treatment in Adults with Spinal Muscular Atrophy","volume":"11","author":"Duong","year":"2021","journal-title":"Neurol. Clin. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/thoraxjnl-2020-216564","article-title":"Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1\u20133","volume":"77","author":"Chacko","year":"2022","journal-title":"Thorax"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ppul.25142","article-title":"Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen","volume":"56","author":"Amaddeo","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","article-title":"Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: A 3-year follow-up study","volume":"4","author":"Scheijmans","year":"2022","journal-title":"Brain Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"Pechmann","year":"2023","journal-title":"Brain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.nmd.2023.04.007","article-title":"Respiratory and sleep outcomes in children with SMA treated with nusinersen-real world experience","volume":"33","author":"Gonski","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e15310","DOI":"10.1111\/ped.15310","article-title":"The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy","volume":"64","author":"Hepkaya","year":"2022","journal-title":"Pediatr. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.nmd.2022.04.003","article-title":"Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3","volume":"32","author":"Fainmesser","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.nmd.2021.01.008","article-title":"A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs","volume":"31","author":"Edel","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13023-023-03008-6","article-title":"Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: A real-life observatory for innovative treatments","volume":"19","author":"Magot","year":"2024","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0883073807305787","article-title":"Molecular mechanisms of spinal muscular atrophy","volume":"22","author":"Sumner","year":"2007","journal-title":"J. Child Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0883073807305668","article-title":"Spinal muscular atrophy diagnostics","volume":"22","author":"Prior","year":"2007","journal-title":"J. Child Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/acn3.51625","article-title":"Biochemical and clinical biomarkers in adult SMA 3\u20134 patients treated with nusinersen for 22 months","volume":"9","author":"Poesen","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","article-title":"An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies","volume":"51","author":"Giess","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6306\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:17:46Z","timestamp":1760113066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":37,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13216306"],"URL":"https:\/\/doi.org\/10.3390\/jcm13216306","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}